Home > Insider Trading > Filing (0001140361-11-010629)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874716	Idexx Laboratories Inc	IDXX	In Vitro & In Vivo Diagnostic Substances (2835)	010393723

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1377232	Phd J Michael Williams	One Idexx Drive Westbrook ME 04092	Corporate Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2011-02-16	1,260	$78.21	9,144	No	4	S	Direct
Common Stock	Disposition	2011-02-16	79	$78.20	9,065	No	4	S	Direct
Common Stock	Acquisiton	2011-02-16	2,472	$25.45	11,537	No	4	M	Direct
Common Stock	Acquisiton	2011-02-16	8,128	$25.45	19,665	No	4	M	Direct
Common Stock	Disposition	2011-02-16	10,600	$78.13	9,065	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Incentive Stock Option (right to buy)	Disposition	2011-02-16	8,128	$0.00	8,128	$25.45
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2011-02-16	2,472	$0.00	2,472	$25.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2014-02-04	No	4	M	Direct
0		2014-02-04	No	4	M	Direct

Footnotes

The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $78.1736 to $78.2800, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $78.0700 to $78.2500, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
Grant of options to buy shares of common stock becomes exercisable as to 1,352 shares on 02/05/2005, 02/05/2006, 02/05/2007, 02/05/2008, and the remaining 2,720 shares on 02/05/2009.
Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/05/2005) of the date of grant.